Rohayem J, Sinthofen N, Nieschlag E, Kliesch S, Zitzmann M
Centre of Reproductive Medicine and Andrology, Department of Clinical Andrology, University of Muenster, Muenster, Germany.
Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.
Andrology. 2016 Jan;4(1):87-94. doi: 10.1111/andr.12128.
Germ cell and Sertoli cell proliferation and maturation in human testes occur in three main waves, during the late fetal and early neonatal period and at early puberty. They are triggered by periods of increased activity of the hypothalamic-pituitary-gonadal (HPG) axis. In hypogonadotropic hypogonadism (HH), these processes are variably disturbed. The objective of this study was to explore whether success of gonadotropin replacement in HH men is predictable by the origin of HH, indicating time of onset and severity of GnRH/gonadotropin deficiency. The data of 51 adult HH patients who had undergone one cycle of hCG/FSH treatment were reviewed. Five groups were established, according to the underlying HH origin. Therapeutic success by final bi-testicular volumes (BTVs) final sperm concentrations (SC) and conception rates were compared and related to baseline parameters, indicative of the degree of HPG-axis disruption. Overall, BTVs rose from 13 ± 15 to 27 ± 15 mL, spermatogenesis was induced in 98%, with mean SCs of 15 ± 30 mill/mL, spontaneous pregnancies in 37% and additional 18% via intracytoplasmic sperm injection. Kallmann syndrome patients had the poorest responses (BTV: 16.9 ± 10 mL; SC: 3.5 ± 5.6 mill/mL), followed by patients with congenital/infancy-acquired multiple pituitary hormone deficiencies (MPHD) and patients with HH+absent puberty (BTV: 21 ± 14/24 ± 9 mL; SC: 5.5 ± 6.5/ 14.5 ± 23.8 mill/mL). HH men with pubertal arrest and with post-pubertally acquired MPHD had the best results (BTV: 36 ± 14/38 ± 16 mL; SC: 25.4 ± 34.2/29.9 ± 50.5 mill/mL). Earlier conception after 20.3 ± 11.5 months (vs. 43.1 ± 43.8; p = 0.047) of gonadotropin treatment with higher pregnancy rates (62% vs. 42%) was achieved in the two post-pubertally acquired HH subgroups, compared to the three pre-pubertally acquired. Therapeutic success was higher in patients without previously undescended testes, with higher baseline BTVs (pre- vs. post-pubertal HH: 5 ± 4 mL vs. 26 ± 16 mL; p < 0.0001) and higher baseline inhibinB levels (pre- vs. post-pubertal HH: 16.6 vs. 144.5 pg/mL; p = 0.0004). The cause of HH is a valuable predictor of outcome of gonadotropin replacement in adults.
人类睾丸中的生殖细胞和支持细胞的增殖与成熟主要发生在三个阶段,即胎儿晚期和新生儿早期以及青春期早期。这些过程由下丘脑 - 垂体 - 性腺(HPG)轴活动增加的时期触发。在低促性腺激素性性腺功能减退(HH)中,这些过程会受到不同程度的干扰。本研究的目的是探讨HH男性中促性腺激素替代治疗的成功是否可通过HH的起源来预测,这表明GnRH/促性腺激素缺乏的发病时间和严重程度。回顾了51例接受过一个周期hCG/FSH治疗的成年HH患者的数据。根据潜在的HH起源建立了五组。比较了最终双侧睾丸体积(BTV)、最终精子浓度(SC)和受孕率的治疗成功率,并将其与指示HPG轴破坏程度的基线参数相关联。总体而言,BTV从13±15 mL增加到27±15 mL,98%的患者诱导了精子发生,平均SC为15±30百万/mL,37%的患者自然受孕,另有18%通过卵胞浆内单精子注射受孕。卡尔曼综合征患者的反应最差(BTV:16.9±10 mL;SC:3.5±5.6百万/mL),其次是先天性/婴儿期获得性多种垂体激素缺乏(MPHD)患者和HH+青春期缺失患者(BTV:21±14/24±9 mL;SC:5.5±6.5/14.5±23.8百万/mL)。青春期停滞和青春期后获得性MPHD的HH男性效果最佳(BTV:36±14/38±16 mL;SC:25.4±34.2/29.9±50.5百万/mL)。与三个青春期前获得性HH亚组相比,两个青春期后获得性HH亚组在促性腺激素治疗20.3±11.5个月后(vs. 43.1±43.8;p = 0.047)受孕更早,妊娠率更高(62% vs. 42%)。以前没有隐睾的患者治疗成功率更高,基线BTV更高(青春期前与青春期后HH:5±4 mL vs. 26±16 mL;p < 0.0001),基线抑制素B水平更高(青春期前与青春期后HH:16.6 vs. 144.5 pg/mL;p = 0.0004)。HH的病因是成人促性腺激素替代治疗结果的一个有价值的预测指标。